Editorial Staff

Study: Shift from Highest-Priced Healthcare Providers Would Generate Tremendous Savings

/in , , , , /by Editorial Staff
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Calls for insurance carrier incentives, training to allow physicians’ staffs to provide resources on lower-cost/high-value providers

BOSTON – Consumers in just one Massachusetts county could have saved nearly $22 million in a single year and $116.6 million adjusted for inflation over four years if they switched from using the most expensive providers for 16 shoppable healthcare services to those whose prices were closer to average, according to a new study published by Pioneer Institute.

“With patient navigators and financial incentives from their insurance carriers to utilize lower cost providers, and support from administrative staff at physicians’ offices to help them find alternative providers and resources, consumers can alter their behavior,” said Barbara Anthony, who authored “Analysis of Spending on Shoppable Services in Massachusetts” with Seher Chowdhury.

The study looked at spending on 16 shoppable services (those that, unlike emergency care, allow consumers to shop for value) in Suffolk County during fiscal 2015.  It calculated the savings that would be achieved by shifting from providers whose prices were in the top 20 percent to those with prices between the 40th and 80th percentile.  Suffolk County consists of Boston, Chelsea, Revere and Winthrop.

Healthcare prices vary widely across Massachusetts, and more expensive care doesn’t generally correlate with better quality.  Healthcare is the only industry in which consumers are unaware of both the overall price and the amount coming out of their pockets for a service at the time they utilize it.  Insured consumers generally know just their co-pay and deductible.

Pioneer surveys have found that three out of four consumers would be interested in incentives like cash-back programs to use lower-cost, high-quality providers.  The Commonwealth’s three largest health insurers – Blue Cross Blue Shield, Harvard Pilgrim and Tufts – offer incentive programs.  The authors recommend that carriers do more to promote the programs to their members.

“Greater utilization of lower-cost/high-value providers would save money for consumers, carriers and reduce overall healthcare costs” said Pioneer Executive Director Jim Stergios.

Anthony and Chowdhury also recommend that administrative staff for primary care physicians and other doctors who make frequent referrals should be trained so they can provide patients with resources such as lists of lower-cost/high-value specialists and imaging centers to allow consumers to make price-conscious decisions that work best for them.

Price transparency has become increasingly important over the last 10-15 years, as cost shifting has resulted in more health insurance policies with high deductibles and increased out-of-pocket costs.

Finally, the authors call on the Commonwealth to use its bully pulpit to spur innovation around incentive programs and to focus on price transparency.  Several Pioneer surveys have shown lax compliance by providers with a law that requires all providers, including physicians, hospitals, dentists, and clinics, to provide consumer price information within two business days upon request.
About the Authors

Barbara Anthony, lawyer, economist, and public policy expert, is a Senior Fellow in Healthcare Policy at the Pioneer Institute. She was also a former Senior Fellow and Associate at the Harvard Kennedy School’s Center for Business and Government where she researched and wrote about Massa­chusetts market reform and healthcare cost containment efforts. She served as Massachusetts Undersecretary of the Office of Consumer Affairs and Business Regulation from 2009 to 2015 and has worked at the intersection of federal and state commercial regulation and the business community for many years. Among other positions, Anthony served as the Director of the Northeast Regional Office of the Federal Trade Commission in Manhattan, and was a top deputy to the Massachusetts Attorney General. She began her career as an Antitrust Trial Attorney at the U.S. Justice Department in Washington, D.C. Anthony is a well-known consumer advocate and regularly appears as a media commentator on consumer protection and business regulation issues.

Seher Chowdhury graduated this Spring from the Boston University School of Public Health (BUSPH) with a Masters Degree in Public Health; her areas of specialization include Health Policy & law and Epidemiology and Biostatistics. She has been a Pioneer Research Assistant in Healthcare Policy since June 2019. She has worked extensively in the area of healthcare price transparency along with Pioneer’s Senior Fellows. She participated extensively in Pioneer’s first state poll and analysis of consumers’ attitudes toward healthcare price transparency. Outside of price transparency, her areas of interest include Medicaid reform and expan­sion; reproductive and minority health access and equity; and the intersection of health, human rights, and bioethics. Seher graduated from the University of California at Los Angeles (UCLA) in 2018 with a Bachelor of Science degree, where she completed a major in Biology and minor in Asian Languages (Korean concentration).

About Pioneer

Mission
Pioneer Institute develops and communicates dynamic ideas that advance prosperity and a vibrant civic life in Massachusetts and beyond.

Vision
Success for Pioneer is when the citizens of our state and nation prosper and our society thrives because we enjoy world-class options in education, healthcare, transportation and economic opportunity, and when our government is limited, accountable and transparent.

Values
Pioneer believes that America is at its best when our citizenry is well-educated, committed to liberty, personal responsibility, and free enterprise, and both willing and able to test their beliefs based on facts and the free exchange of ideas.

Get Updates On Our Healthcare Research and Events!


Related Posts:

COVID’s Unintended Victims: Traditional Diseases Overlooked at the Public’s Peril

This week on Hubwonk, host Joe Selvaggi talks with Pioneer Institute’s Visiting Fellow in Life Sciences, Dr. Bill Smith, about his newest research paper, “An “Impending Tsunami” in Mortality from Traditional Diseases,” which sounds the alarm that the public health community’s focus on COVID-19 has caused many to avoid seeking medical attention for other illnesses. As a result, more Americans are dying from fear of COVID than from the disease itself.

Vaccine Development Renaissance: Pandemic Brings Niche Industry into Mainstream

This week on Hubwonk, host Joe Selvaggi talks with virologist, Dr. Peter Kolchinsky, about the explosion of vaccine technologies and innovations brought into the spotlight by the massive investment to fight the pandemic, and dives deeply into the exciting promise of vaccines to combat an ever-widening range of disease.

Shifting COVID-19 Goalposts: Moving from Zero Infections to Zero Deaths

This week on Hubwonk, host Joe Selvaggi talks with surgeon and author Dr. Marty Makary about the power and durability of vaccines, natural immunity and clinical therapies, that are overshadowed by the public health community's continued target of zero COVID-19 infections.
A Woman Helping a Disabled Man in a Wheelchair

An Act advancing health care research and decision-making centered on patients and people with disabilities

On November 9th, 2021, William Smith, Pioneer Institute Visiting Fellow in Life Sciences, submitted the following testimony to the Massachusetts Legislature in support of House Bill 201, which addresses a number of flaws and infirmities in the Quality Adjusted Life Years (QALYs) methodology that is utilized by a number of foreign nations in evaluating the value of medicines.

An “Impending Tsunami” in Mortality from Traditional Diseases?

This report examines whether, after the COVID-19 pandemic subsides, the U.S. will have another looming public health crisis emerging from patients failing to have had their cardiology needs addressed properly during the lockdowns. Moreover, if we surmise that a follow-on public health crisis will emerge, we can also conclude that certain population segments are going to be more impacted by CVD, as there are documented health disparities in this therapeutic area. Finally, there are policy changes that could be taken to mitigate a possible spike in CVD adverse events; the paper will close by recommending certain policy changes.

Study: Decline in Cardiovascular Health Screenings During COVID-19 Pandemic Poses New Public Health Threat

Pioneer Institute today released a new analysis focused on cardiovascular disease, An “Impending Tsunami” in Mortality from Traditional Diseases?, that examines how the COVID-19 pandemic has created another unrelated public health crisis. The Pioneer analysis examines how a single-minded public health focus on COVID-19, social distancing, and lockdowns drove reductions in screenings, diagnoses, and early treatment for complex conditions such as heart disease.

A Modest Proposal to Raise Federal Revenue

As a way to tackle drug prices, President Joe Biden recently announced that he supports the so-called “inflation rebate,” which would require drug companies to give the federal government any revenue from Medicare drug prices above the general rate of inflation. Senate Finance Committee Chairman Ron Wyden and House Speaker Nancy Pelosi have also publicly endorsed the inflation rebate.

Why are health care costs rising every year in Massachusetts?

0 Comments
/
The largest driver is the increase in prices by health systems that have the clout to command higher payments and work to recruit more patients to their high-cost facilities.

Untangling Variants & Outbreaks: Can Vaccines & Natural Immunity Outrun Delta?

Hubwonk host Joe Selvaggi talks with author, surgeon, and public health expert Dr. Marty Makary about the COVID-19 Delta Variant, the durability of natural and vaccinated immunity, the benefits of booster shots, and the health risks for children as we move into the fall.

Targeting Pharma: Infrastructure Bill Employs Price Controls To Offset Unprecedented Price Tag

Hubwonk host Joe Selvaggi talks with Pioneer Institute Visiting Fellow in Life Sciences Dr. William Smith about how the price control features of the emerging $3.5 trillion infrastructure bill might affect the pharmaceutical Industry, both nationwide and here in Massachusetts, and what effect that change will have on drug consumers.